Global Parkinsons disease Drug Market Research Report 2019 (Includes Business Impact of COVID-19)
- TBI270058
- May 03, 2019
- Global
- 107 pages
- QY Market Research
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Parkinsons disease Drug market.
Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Parkinsons disease Drug market."
Researchers are working to develop new and improved therapies for people with Parkinsons disease (PD). There have been many drugs that have been approved to treat Parkinson disease.
The global Parkinsons disease Drug market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Parkinsons disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Parkinsons disease Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Teva
Novartis AG
GSK
AbbVie
Merck
Boehringer Ingelheim
Impax Laboratories
Lundbeck
Sun Pharma
Wockhardt
UCB
Valeant Pharmaceuticals
Acadia
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Carbidopa/Levodopa
Dopamine Receptor Agonists
MAO-Inhibitors
Segment by Application
Hospital
Online
Retail Pharmacies
Table of Contents
Executive Summary
1 Parkinsons disease Drug Market Overview
1.1 Product Overview and Scope of Parkinsons disease Drug
1.2 Parkinsons disease Drug Segment by Type
1.2.1 Global Parkinsons disease Drug Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Carbidopa/Levodopa
1.2.3 Dopamine Receptor Agonists
1.2.4 MAO-Inhibitors
1.3 Parkinsons disease Drug Segment by Application
1.3.1 Parkinsons disease Drug Consumption Comparison by Application (2014-2025)
1.3.2 Hospital
1.3.3 Online
1.3.4 Retail Pharmacies
1.4 Global Parkinsons disease Drug Market by Region
1.4.1 Global Parkinsons disease Drug Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global Parkinsons disease Drug Market Size
1.5.1 Global Parkinsons disease Drug Revenue (2014-2025)
1.5.2 Global Parkinsons disease Drug Production (2014-2025)
2 Global Parkinsons disease Drug Market Competition by Manufacturers
2.1 Global Parkinsons disease Drug Production Market Share by Manufacturers (2014-2019)
2.2 Global Parkinsons disease Drug Revenue Share by Manufacturers (2014-2019)
2.3 Global Parkinsons disease Drug Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Parkinsons disease Drug Production Sites, Area Served, Product Types
2.5 Parkinsons disease Drug Market Competitive Situation and Trends
2.5.1 Parkinsons disease Drug Market Concentration Rate
2.5.2 Parkinsons disease Drug Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion
3 Global Parkinsons disease Drug Production Market Share by Regions
3.1 Global Parkinsons disease Drug Production Market Share by Regions
3.2 Global Parkinsons disease Drug Revenue Market Share by Regions (2014-2019)
3.3 Global Parkinsons disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Parkinsons disease Drug Production
3.4.1 North America Parkinsons disease Drug Production Growth Rate (2014-2019)
...
| read more...
Related Reports
